<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00959842</url>
  </required_header>
  <id_info>
    <org_study_id>LVZ 112860</org_study_id>
    <secondary_id>GSK - LVZ 112860</secondary_id>
    <nct_id>NCT00959842</nct_id>
  </id_info>
  <brief_title>Effects of Lovaza on Lipoprotein Composition and Function in Mild Hypertriglyceridemia</brief_title>
  <acronym>ELLF</acronym>
  <official_title>Effects of Lovaza on Lipoprotein Composition and Function in Mild Hypertriglyceridemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanford Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanford Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will build upon a previous finding that showed a triglyceride lowering effect of&#xD;
      prescription omega-3 in combined therapy with statins. The proposed study will use a simple&#xD;
      change from baseline design on 15 subjects who are hypertriglyceridemic on stable statin&#xD;
      therapy. The protocol involves 3 study visits; each involve drawing a blood sample: day 1 -&#xD;
      screening (blood draw for qualification and safety); day 7 - before taking prescription&#xD;
      omega-3 fatty acids (Lovaza, 4 capsules/d; GlaxoSmithKline), day 63 -after taking&#xD;
      prescription omega-3 fatty acids (Lovaza, 4 capsules/d; GlaxoSmithKline). The proposed study&#xD;
      will include up to 15 subjects and will utilize several different measures of lipoprotein&#xD;
      structure and function. The investigators will measure functional parameters such as the&#xD;
      binding affinity of lipoproteins before and after treatment with omega-3 fatty acids. The&#xD;
      investigators will also measure fatty acid, oxylipin and apolipoprotein content of plasma,&#xD;
      very-low-density lipoprotein (VLDL), low-density lipoprotein (LDL) and high-density&#xD;
      lipoprotein (HDL).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will build upon a previous finding that showed a triglyceride lowering effect of&#xD;
      prescription omega-3 in combined therapy with statins. The proposed study will use a simple&#xD;
      change from baseline design on 15 subjects who are hypertriglyceridemic on stable statin&#xD;
      therapy. The protocol involves 3 study visits; each involve drawing a blood sample: day 1 -&#xD;
      screening (blood draw for qualification and safety); day 7 - before taking prescription&#xD;
      omega-3 fatty acids (Lovaza, 4 capsules/d; GlaxoSmithKline), day 63 -after taking&#xD;
      prescription omega-3 fatty acids (Lovaza, 4 capsules/d; GlaxoSmithKline). The proposed study&#xD;
      will include up to 15 subjects and will utilize several different measures of lipoprotein&#xD;
      structure and function. The investigators will measure functional parameters such as the&#xD;
      binding affinity of lipoproteins before and after treatment with omega-3 fatty acids. The&#xD;
      investigators will also measure fatty acid, oxylipin and apolipoprotein content of plasma,&#xD;
      very-low-density lipoprotein (VLDL), low-density lipoprotein (LDL) and high-density&#xD;
      lipoprotein (HDL).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HDL 15-HEPE</measure>
    <time_frame>4 months</time_frame>
    <description>high density lipoprotein level of 15-HEPE</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>Lovaza</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lovaza was given as the only agent; there was no comparator agent or arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lovaza</intervention_name>
    <description>1 gram gel capsule 4 capsules per day for 8 weeks</description>
    <arm_group_label>Lovaza</arm_group_label>
    <other_name>Omega-3 Fatty Acid</other_name>
    <other_name>fish oil</other_name>
    <other_name>Omacor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-79 years&#xD;
&#xD;
          -  Stable does of statins ≥ 8 weeks prior to screening&#xD;
&#xD;
          -  Good health by medical history, physical exam, electrocardiogram, laboratory test&#xD;
             (e.g., serum chem., urinalysis)&#xD;
&#xD;
          -  Mean fasting serum triglyceride of two most recent tests in medical record ≥ 200 and &lt;&#xD;
             500 mg/dL&#xD;
&#xD;
          -  Mean LDL-cholesterol of two most recent tests in medical record ≤ 1.1 × NCEP ATP III&#xD;
             goal&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medications, vitamin pills, nutritional supplements or herbal preparations deemed&#xD;
             exclusionary per primary investigator for possible interference&#xD;
&#xD;
          -  Poorly controlled diabetes mellitus (e.g. [HbA1c] &gt; 8.0%)&#xD;
&#xD;
          -  History of a cardiovascular event&#xD;
&#xD;
          -  Past revascularization procedure&#xD;
&#xD;
          -  Past aortic aneurysm or an aortic dissection &lt; 6 months prior to screening&#xD;
&#xD;
          -  History of pancreatitis&#xD;
&#xD;
          -  Sensitivity to any statin OR to omega-3 fatty acids or fish products&#xD;
&#xD;
          -  Poorly controlled hypertension (i.e.: &gt;=160 systolic (resting) and/or &gt;=100 diastolic&#xD;
             (resting)) at 2 consecutive visits&#xD;
&#xD;
          -  Serum Creatinine ≥ 2.0 mg/dL&#xD;
&#xD;
          -  Serum transaminase &gt; 1.5 × upper limit of normal (ULN); including aspartate&#xD;
             aminotransferase [AST] or alanine aminotransferase [ALT]; 31 U/L for AST, 45 U/L for&#xD;
             ALT&#xD;
&#xD;
          -  Creatine Kinase (CK) &gt; 3.0 × ULN&#xD;
&#xD;
          -  Taking other triglyceride lowering drugs (e.g., niacin, fibrates) or fish oil&#xD;
             supplements providing more than 500 mg of EPA+DHA per day&#xD;
&#xD;
          -  Contraindications for Lovaza per product insert&#xD;
&#xD;
          -  Women who are pregnant or nursing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory C Shearer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sanford Research/USD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanford Research/USD</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 14, 2009</study_first_submitted>
  <study_first_submitted_qc>August 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2009</study_first_posted>
  <results_first_submitted>September 23, 2021</results_first_submitted>
  <results_first_submitted_qc>September 23, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 20, 2021</results_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sanford Research</investigator_affiliation>
    <investigator_full_name>William S. Harris</investigator_full_name>
    <investigator_title>Adjunct Senior Scientist</investigator_title>
  </responsible_party>
  <keyword>hypertriglyceridemia</keyword>
  <keyword>Omega-3 Fatty Acids</keyword>
  <keyword>Lipoprotein</keyword>
  <keyword>Statin</keyword>
  <keyword>Lovaza</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients on statins with persistent hypertriglyceridemia were identified by EMR search of hospital records. Letters were sent to eligible and those responding were screened and if qualifying, enrolled.</recruitment_details>
      <pre_assignment_details>No run in or wash out</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lovaza</title>
          <description>Lovaza was given as the only agent; there was no comparator agent or arm&#xD;
Lovaza: 1 gram gel capsule 4 capsules per day for 8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15">17 were recruited and at baseline. 2 dropped out before starting the study drug. 15 finished</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lovaza</title>
          <description>Lovaza was given as the only agent; there was no comparator agent or arm Lovaza: 1 gram gel capsule 4 capsules per day for 8 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" lower_limit="46" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>lipids</title>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <title>LDL-C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88" lower_limit="78" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" lower_limit="33" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="237" lower_limit="200" upper_limit="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HDL 15-HEPE</title>
        <description>high density lipoprotein level of 15-HEPE</description>
        <time_frame>4 months</time_frame>
        <population>hypertriglyceridemic statin treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>Lovaza</title>
            <description>Lovaza was given as the only agent; there was no comparator agent or arm Lovaza: 1 gram gel capsule 4 capsules per day for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>HDL 15-HEPE</title>
          <description>high density lipoprotein level of 15-HEPE</description>
          <population>hypertriglyceridemic statin treated patients</population>
          <units>nmol/mmol phospholipid</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" lower_limit="2.7" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>final</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" lower_limit="9.5" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment Group</title>
          <description>all patients were treated with n3</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Greg Shearer</name_or_title>
      <organization>Professor</organization>
      <phone>814-867-3040</phone>
      <email>gcs13@psu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

